MedTrace Logo

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

NCT02292433 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-03-15

Study results available
· View outcomes & findings →

Summary

Study B1621018 will assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Dose Levels of Pf-04937319 in Japanese Subjects with Type 2 Diabetes Mellitus As Monotherapy

Conditions

Interventions

DRUG

PF-04937319 high dose

tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days

DRUG

PF-04937319 low dose

tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days

DRUG

Placebo

tablets, breakfast plus lunch, 7 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Japan

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02292433 on ClinicalTrials.gov